Navigation Links
Tumor Painting to Fight Against Cancer

A tumor paint developed by researchers at Seattle Childrens Hospital Research Institute and Fred Hutchinson Cancer Research Center will help surgeons see where a tumor begins and ends more precisely by illuminating the cancerous cells.

The paint is a scorpion-derived peptide called chlorotoxin that is linked to the molecular beacon Cy5.5.Until now there has been no way to allow surgeons to see tumors live during surgery.

Chlorotoxin:Cy5.5 is a fluorescent molecular beacon that emits photons in the near infrared spectrum. This illumination gives surgeons a better chance of removing all of the cancerous cells during surgery without injuring surrounding healthy tissue.

This is particularly significant in the brain, where approximately 80% of malignant cancers recur at the edges of the surgical site. Current technology, such as magnetic resonance imaging (MRI) can distinguish tumors from healthy tissue only if more than 1 million cancer cells are present.

But Cy5.5 can identify tumors with as few as 2000 cancer cells, making it 500 times more sensitive than MRI.

"My greatest hope is that tumor paint will fundamentally improve cancer therapy, said James M. Olson, MD, PhD, of Seattle Childrens Hospital and The Hutchison Center who is the senior author of the study. By allowing surgeons to see cancer that would be undetectable by other means, we can give our patients better outcomes.

Olson led the team that included neurosurgeons, engineers and biologists. The bioconjugate, Chlorotoxin:Cy5.5 which, when injected, emits a near-infrared light, was created in his laboratory at the Hutchinson Center.

In mouse models, the team demonstrated that they could light up brain tumors as small as 1 millimeter in diameter without lighting up the surrounding normal brain tissue. In a prostate cancer model, as few as 200 cancer cells traveling in a mouse lymph channel could be detected.

Chlorotoxin:Cy5.5 is applicable to many cancers, but is especially helpful to surgeons operating on brain tumors. Not only would it reveal whether theyd left behind any bits of tumor, it would also help them avoid removing normal tissue.

Chlorotoxin:Cy5.5 activates within hours and it begins binding to cancer cells within minutes. The Chlorotoxin:Cy5.5 signal lasts for 14 days, illuminating cancer cells. Contrast agents currently in use only last for a few minutes.

I feel fortunate to be working with gifted scientists to bring this revolutionary imaging technique from the laboratory to the bedside, said Richard Ellenbogen, MD, Pediatric Neurosurgeon, Seattle Children's Hospital and co-investigator on the study. This development has the potential to save lives and make brain tumor resection safer.

Surgery remains a primary form of cancer therapy. Despite advances in surgical tools, surgeons currently rely on color, texture or blood supply to differentiate tumor from normal tissue, a distinction that is often subtle and imperfect.

The limitations of this method contribute to cancer growth or patient mortality that is potentially preventable. The tumor painting technique combines a visual guide for the surgeon with the potential for significant improvement in accuracy and safety.

Tumor painting has been successfully tested in mice and the pilot safety trials are complete. Olson and his team are preparing the necessary toxicity studies before seeking approval from the Food and Drug Administration to begin clinical trials.

Chlorotoxin:Cy5.5 could be used in operating rooms in as little as 18 months. All clinical studies will have consenting adult participants. Olson and his team believe that Chlorotoxin:Cy5.5 has the potential to be used in the future as a non-invasive screening tool for early detection of skin, cervical, esophageal, colon and lung cancers.

It is al so useful in identifying positive lymph nodes which could mean a significant advancement for breast, prostate and testicular cancers.

For more information about the Institute visit http: research.seattlechildrens.org/.


'"/>




Related medicine news :

1. Use of Cellular Phones associated with Increased risk of Brain Tumors
2. Radiofrequency Energy Cooks Tumors Without Surgery
3. New Liver Tumor Treatment
4. Latest Tumor Classification More Informative
5. New Technique For Benign Breast Tumors
6. Another Treatment Option for Benign Tumors
7. Understanding The Origin Of Tumors
8. Outpatient Treatment Possible For Patients with Uterine Fibroid Tumors
9. Stem Cells, Tumor Cells Share Similar Properties: Scope For Treatment and Prevention?
10. Lipoma Arborescens: A Rare Tumor Of The Knee
11. Researchers Develop Mouse Model Of Brain Tumor
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/28/2017)... ... May 28, 2017 , ... Florida Pain ... announce that Sheldon K. Cho, MD, has joined its Winter Haven practice. ... concentrates on minimally invasive techniques to treat and manage many types of pain. ...
(Date:5/27/2017)... (PRWEB) , ... May 27, 2017 , ... From May ... and Oticon. The three-day event was held at the Marriott Syracuse Downtown Hotel in ... the hearing brand and network of independent hearing healthcare providers to help them stay ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... new educational seminar to focus on current legislative activity and the latest regulatory ... at 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. 11, ...
(Date:5/26/2017)... , ... May 26, 2017 , ... ... first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical ... “We are thrilled to partner with Cupron® to provide customers with a ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Rob Lowe ... An upcoming production of the series is on hiking in American. Viewers can reconnect ... of the great benefits of hiking. , Many consumers have looked for an inventive ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... MACRA replaces the outdated sustainable growth ... reimbursement. Black Book Research crowdsource-surveyed 8,845 physician practices from ... Market for MIPS Compliance Technology is Booming ... 3 or more clinicians seek to buy Merit-Based Incentive ... magnitude of the changes, the hunt is on for ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
(Date:5/6/2017)... 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), has ... square feet to its Welch Allyn campus. ... to bring more than 100 new jobs to ... has maintained a significant presence for more than 100 ... positions, a large portion of which will be R&D ...
Breaking Medicine Technology: